Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote (71)	3/17/1999 12:49:00 AM
From: RCMac	of 52153

>>I follow [CORR] and will post on integrelin if anyone cares.<< David, I hold a small slug of CORR as well, as you know, and I'd be delighted to see your thoughts on Integrelin sales. FYI, here are another SI contributor's Integrelin estimates as of a couple of months ago: Message 7578160 "Now here is where the market is short-sighted. CORR will likely do $70 million end-user sales [of Integrelin] in 1999. This should grow to $150-200 million by 2001." Assuming you have a sales estimate for Integrelin, or adopt the one quoted above, how do you translate that into an estimate of valuation (aside from feeling in your value-player bones that it's real cheap at these levels, and ought to attract CHIR's or someone's attention). And how would you assign a value to CORR's next product, Cromafiban, an oral GP IIb-IIIa inhibitor now in Phase II? Here is CORR's recent press release on Cromafiban: biz.yahoo.com --RCM

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next